Medical Developments International Limited
Simbolis: MVP.AX
ASX
0.59
AUDRinkos kaina šiandien
-2.0215
P/E santykis
0.1080
PEG koeficientas
50.92M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Medical Developments International Limited (MVP-AX) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 97.88 | 24.7 | 20.4 | 36.3 | |||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.net-receivables | 26.01 | 8.9 | 6.2 | 5 | |||||||||||||||||||||
balance-sheet.row.inventory | 35.57 | 8.4 | 7.1 | 5.7 | |||||||||||||||||||||
balance-sheet.row.other-current-assets | 3.35 | 0.8 | 0.6 | 0.4 | |||||||||||||||||||||
balance-sheet.row.total-current-assets | 162.8 | 42.8 | 34.4 | 47.4 | |||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 46.89 | 12.1 | 11.6 | 11.7 | |||||||||||||||||||||
balance-sheet.row.goodwill | 7.62 | 3.8 | 3.8 | 4.4 | |||||||||||||||||||||
balance-sheet.row.intangible-assets | 92.91 | 8.5 | 8 | 8.2 | |||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 100.53 | 12.3 | 11.8 | 12.6 | |||||||||||||||||||||
balance-sheet.row.long-term-investments | 32.04 | -3.8 | -3.8 | -4.4 | |||||||||||||||||||||
balance-sheet.row.tax-assets | 45.75 | 16.3 | 14.8 | 2.2 | |||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 22.91 | 29.9 | 32.7 | 30.6 | |||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 248.12 | 66.7 | 67 | 52.8 | |||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-assets | 410.92 | 109.5 | 101.4 | 100.2 | |||||||||||||||||||||
balance-sheet.row.account-payables | 47.97 | 13.3 | 9.4 | 3.3 | |||||||||||||||||||||
balance-sheet.row.short-term-debt | 1.41 | 0.4 | 0.3 | 0.3 | |||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 9.08 | 2.2 | 2.5 | 2.7 | |||||||||||||||||||||
Deferred Revenue Non Current | 27.5 | 1.9 | 21.6 | 21.9 | |||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 17.31 | - | - | - | |||||||||||||||||||||
balance-sheet.row.other-current-liab | 2.73 | 1.6 | 0.7 | 3.3 | |||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 55.4 | 12.6 | 33.6 | 24.9 | |||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 9.08 | 2.2 | 2.5 | 2.7 | |||||||||||||||||||||
balance-sheet.row.total-liab | 108.23 | 28.2 | 44.1 | 31.9 | |||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.common-stock | 393.8 | 105.7 | 77 | 76.9 | |||||||||||||||||||||
balance-sheet.row.retained-earnings | -109.4 | -30.2 | -24.5 | -12.1 | |||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 18.28 | 5.7 | 4.9 | 3.5 | |||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 302.68 | 81.3 | 57.3 | 68.3 | |||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 410.92 | 109.5 | 101.4 | 100.2 | |||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-equity | 302.68 | 81.3 | 57.3 | 68.3 | |||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 410.92 | - | - | - | |||||||||||||||||||||
Total Investments | 32.04 | -3.8 | -3.8 | -4.4 | |||||||||||||||||||||
balance-sheet.row.total-debt | 10.49 | 2.6 | 2.8 | 3 | |||||||||||||||||||||
balance-sheet.row.net-debt | -87.39 | -22.1 | -17.6 | -33.2 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -21.58 | -5.6 | -12.4 | -12.6 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 6.14 | 3.1 | 2.9 | 3.7 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | -16.12 | -7.4 | -8.4 | -0.1 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 7.08 | 1.3 | 1 | 1.2 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | -9.12 | -2.5 | -3.6 | -9.9 | ||||||||||||||||||||
cash-flows.row.account-receivables | -1.4 | -2.9 | -2.5 | 1.4 | ||||||||||||||||||||
cash-flows.row.inventory | -3.45 | -1.8 | -1.4 | 0.2 | ||||||||||||||||||||
cash-flows.row.account-payables | 0.48 | 4.8 | 2.3 | 1 | ||||||||||||||||||||
cash-flows.row.other-working-capital | -2.87 | -2.6 | -2.1 | -12.5 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 4.83 | -5.4 | 9.8 | 8.9 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -28.71 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -11.45 | -7.7 | -5.2 | -6.6 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | -7.54 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -11.45 | -7.7 | -5.2 | -6.6 | ||||||||||||||||||||
cash-flows.row.debt-repayment | -0.26 | -0.3 | -0.2 | -0.1 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 28.57 | 28.3 | 0.4 | 36.3 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | -0.53 | -1.7 | 0 | -0.7 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | -26.4 | -0.1 | -35.5 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 27.79 | 28.1 | 0.1 | 36.1 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 27.54 | 28.1 | 0.1 | 36.1 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.05 | 0.4 | -0.1 | 0 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | -12.58 | 4.3 | -15.9 | 20.7 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 97.88 | 24.7 | 20.4 | 36.3 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 110.45 | 20.4 | 36.3 | 15.5 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | -28.71 | -16.5 | -10.7 | -8.8 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | -11.45 | -7.7 | -5.2 | -6.6 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | -40.16 | -24.2 | -15.9 | -15.4 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 60.19 | 32.3 | 21.9 | 25.3 | |||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 58.93 | 34.9 | 25 | 8.6 | |||||||||||||||||||||
income-statement-row.row.gross-profit | 1.26 | -2.5 | -3.1 | 16.7 | |||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||
income-statement-row.row.research-development | 0.34 | - | - | - | |||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 34.33 | - | - | - | |||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 6.63 | - | - | - | |||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 19.1 | 0 | 0 | |||||||||||||||||||||
income-statement-row.row.operating-expenses | 40.96 | 17.8 | 12.6 | 21.9 | |||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 99.89 | 52.6 | 37.6 | 30.5 | |||||||||||||||||||||
income-statement-row.row.interest-income | 0.93 | 0.7 | 0.5 | 0.1 | |||||||||||||||||||||
income-statement-row.row.interest-expense | 0.19 | 0.1 | 0.1 | 0.1 | |||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 6.63 | - | - | - | |||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 12.96 | 12.8 | -0.2 | -9.7 | |||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 19.1 | 0 | 0 | |||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 12.96 | 12.8 | -0.2 | -9.7 | |||||||||||||||||||||
income-statement-row.row.interest-expense | 0.19 | 0.1 | 0.1 | 0.1 | |||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 6.14 | 3.1 | 2.9 | 3.7 | |||||||||||||||||||||
income-statement-row.row.ebitda-caps | -33.56 | - | - | - | |||||||||||||||||||||
income-statement-row.row.operating-income | -39.7 | -20.3 | -15.7 | -5.2 | |||||||||||||||||||||
income-statement-row.row.income-before-tax | -26.73 | -7.5 | -15.9 | -15 | |||||||||||||||||||||
income-statement-row.row.income-tax-expense | -5.15 | -1.9 | -3.5 | -2.4 | |||||||||||||||||||||
income-statement-row.row.net-income | -21.58 | -5.6 | -12.4 | -12.6 |
Dažnai užduodami klausimai
Kas yra Medical Developments International Limited (MVP.AX) bendras turtas?
Medical Developments International Limited (MVP.AX) bendras turtas yra 109486000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 33494000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra -0.215.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -0.239.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -0.574.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -0.750.
Kas yra Medical Developments International Limited (MVP.AX) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -5609000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 2560000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 17757000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 15699000.000.